 |
市場調査レポート
商品コード
1293814
インフルエンザワクチン市場：ワクチンタイプ、年齢層、投与経路、流通チャネル別-2023-2030年の世界予測Influenza Vaccine Market by Vaccine Type, Age Group, Administration Route, Distribution Channel - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
| インフルエンザワクチン市場：ワクチンタイプ、年齢層、投与経路、流通チャネル別-2023-2030年の世界予測 |
|
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 図表
- 目次
インフルエンザワクチンの世界市場は大きく成長すると予測され、2023年には79億2,137万米ドルが予測され、CAGRは8.97%、2030年には144億9,161万米ドルに達すると予測されています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは世界のインフルエンザワクチン市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。
市場シェア分析
市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。
本レポートは、以下のポイントに関する洞察を提供します：
1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。
2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。
3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。
4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。
5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。
6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。
本レポートは、以下のような質問にお答えします：
1.インフルエンザワクチンの世界市場規模および予測は？
2.予測期間中、世界のインフルエンザワクチン市場を形成するCOVID-19の阻害要因と影響は？
3.インフルエンザワクチンの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？
4.インフルエンザワクチンの世界市場における競争戦略は？
5.インフルエンザワクチンの世界市場における技術動向と規制の枠組みは？
6.インフルエンザワクチンの世界市場における主要ベンダーの市場シェアは？
7.インフルエンザワクチンの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？
目次
第1章 序文
第2章 調査手法
第3章 エグゼクティブサマリー
第4章 市場の概要
第5章 市場洞察
- 市場力学
- 促進要因
- 呼吸器疾患の有病率の増加
- インフルエンザウイルス感染予防のための主要な公衆衛生対策としての予防接種
- 季節性インフルエンザの臨床試験とワクチン開発が進行中
- 呼吸器の健康をサポートする政府の取り組み
- 抑制要因
- 不十分な配信インフラストラクチャの欠如と認識の限界
- 機会
- 主要な市場プレーヤー別研究開発費の増加
- 流通と開発の協力を通じてワクチンの入手可能性を高める
- 動物インフルエンザAウイルスに対するいくつかのワクチン候補が開発中
- 課題
- 呼吸器疾患ワクチンに対する顧客の信頼と自信
- ワクチンの研究開発は株の絶え間ない変動別困難に直面している
- 促進要因
- 市場動向
- COVID-19の累積的な影響
- ロシア・ウクライナ紛争の累積的影響
- 高インフレの累積的影響
- ポーターのファイブフォース分析
- バリューチェーンとクリティカルパス分析
- 規制の枠組み
- 顧客のカスタマイズ
- 新型コロナウイルス：積極的なワクチン開発に注目
- 予防接種の小売薬局への移行
第6章 インフルエンザワクチン市場ワクチンの種類別
- 不活化ワクチン
- 生ワクチン
- 組み換え
第7章 インフルエンザワクチン市場：年齢層別
- 青少年の予防接種
- 成人の予防接種
- 乳児の予防接種
第8章 インフルエンザワクチン市場投与経路別
- 筋肉内
- 鼻腔内
- オーラル
第9章 インフルエンザワクチン市場：流通チャネル別
- 政府医療局
- 病院とクリニック
- 小売薬局
- 救急治療室
第10章 南北アメリカのインフルエンザワクチン市場
- アルゼンチン
- ブラジル
- カナダ
- メキシコ
- 米国
第11章 アジア太平洋地域のインフルエンザワクチン市場
- オーストラリア
- 中国
- インド
- インドネシア
- 日本
- マレーシア
- フィリピン
- シンガポール
- 韓国
- 台湾
- タイ
- ベトナム
第12章 欧州・中東・アフリカのインフルエンザワクチン市場
- デンマーク
- エジプト
- フィンランド
- フランス
- ドイツ
- イスラエル
- イタリア
- オランダ
- ナイジェリア
- ノルウェー
- ポーランド
- カタール
- ロシア
- サウジアラビア
- 南アフリカ
- スペイン
- スウェーデン
- スイス
- トルコ
- アラブ首長国連邦
- 英国
第13章 競合情勢
- FPNVポジショニングマトリクス
- 市場シェア分析：主要企業別
- 競合シナリオ分析：主要企業別
第14章 掲載企業一覧
第15章 付録
- ディスカッションガイド
- ライセンスと価格について
LIST OF FIGURES
- FIGURE 1. INFLUENZA VACCINE MARKET RESEARCH PROCESS
- FIGURE 2. INFLUENZA VACCINE MARKET SIZE, 2022 VS 2030
- FIGURE 3. INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2022 VS 2030 (%)
- FIGURE 5. INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2022 VS 2030 (%)
- FIGURE 6. INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2022 VS 2030 (%)
- FIGURE 7. INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
- FIGURE 8. INFLUENZA VACCINE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
- FIGURE 9. INFLUENZA VACCINE MARKET DYNAMICS
- FIGURE 10. INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 11. INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 12. INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 13. INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 14. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 16. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
- FIGURE 18. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
- FIGURE 19. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2022
LIST OF TABLES
- TABLE 1. INFLUENZA VACCINE MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
- TABLE 3. INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 5. INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
- TABLE 6. INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
- TABLE 7. INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 8. INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 9. INFLUENZA VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. INFLUENZA VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. INFLUENZA VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 13. INFLUENZA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. INFLUENZA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. INFLUENZA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 17. INFLUENZA VACCINE MARKET SIZE, BY GOVERNMENT MEDICAL OFFICE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 18. INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL & CLINIC, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20. INFLUENZA VACCINE MARKET SIZE, BY URGENT CARE UNIT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 22. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 23. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 24. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 25. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 26. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 27. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 28. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 29. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 30. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 31. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 32. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 33. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 34. CANADA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 35. CANADA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 36. CANADA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 37. CANADA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 38. MEXICO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 39. MEXICO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 40. MEXICO INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 41. MEXICO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 42. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 43. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 44. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 45. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 46. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 47. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 48. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 49. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 50. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 51. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 52. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 53. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 54. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 55. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 56. CHINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 57. CHINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 58. CHINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 59. CHINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 60. INDIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 61. INDIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 62. INDIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 63. INDIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 64. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 65. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 66. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 67. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 68. JAPAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 69. JAPAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 70. JAPAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 71. JAPAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 72. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 73. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 74. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 75. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 76. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 77. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 78. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 79. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 80. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 81. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 82. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 83. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 84. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 85. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 86. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 87. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 88. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 89. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 90. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 91. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 92. THAILAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 93. THAILAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 94. THAILAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 95. THAILAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 96. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 97. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 98. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 99. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 100. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 101. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 102. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 103. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 104. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 105. DENMARK INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 106. DENMARK INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 107. DENMARK INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 108. DENMARK INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 109. EGYPT INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 110. EGYPT INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 111. EGYPT INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 112. EGYPT INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 113. FINLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 114. FINLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 115. FINLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 116. FINLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 117. FRANCE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 118. FRANCE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 119. FRANCE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 120. FRANCE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 121. GERMANY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 122. GERMANY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 123. GERMANY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 124. GERMANY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 125. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 126. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 127. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 128. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 129. ITALY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 130. ITALY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 131. ITALY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 132. ITALY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 133. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 134. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 135. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 136. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 137. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 138. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 139. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 140. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 141. NORWAY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 142. NORWAY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 143. NORWAY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 144. NORWAY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 145. POLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 146. POLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 147. POLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 148. POLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 149. QATAR INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 150. QATAR INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 151. QATAR INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 152. QATAR INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 153. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 154. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 155. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 156. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 157. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 158. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 159. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 160. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 161. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 162. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 163. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 164. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 165. SPAIN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 166. SPAIN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 167. SPAIN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 168. SPAIN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 169. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 170. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 171. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 172. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 173. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 174. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 175. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 176. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 177. TURKEY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 178. TURKEY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 179. TURKEY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 180. TURKEY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 181. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 182. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 183. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 184. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 185. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
- TABLE 186. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
- TABLE 187. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
- TABLE 188. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 189. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
- TABLE 190. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2022
- TABLE 191. INFLUENZA VACCINE MARKET LICENSE & PRICING
The Global Influenza Vaccine Market is forecasted to grow significantly, with a projected USD 7,921.37 million in 2023 at a CAGR of 8.97% and expected to reach a staggering USD 14,491.61 million by 2030.
The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Influenza Vaccine Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.
Market Segmentation & Coverage:
This research report categorizes the Global Influenza Vaccine Market in order to forecast the revenues and analyze trends in each of following sub-markets:
Based on Vaccine Type, market is studied across Inactivated, Live Attenuated, and Recombinant. The Recombinant is projected to witness significant market share during forecast period.
Based on Age Group, market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination. The Infant Vaccination is projected to witness significant market share during forecast period.
Based on Administration Route, market is studied across Intramuscular, Intranasal, and Oral. The Intranasal is projected to witness significant market share during forecast period.
Based on Distribution Channel, market is studied across Government Medical Office, Hospital & Clinic, Retail Pharmacy, and Urgent Care Unit. The Urgent Care Unit is projected to witness significant market share during forecast period.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 38.17% in 2022, followed by Americas.
Market Statistics:
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is essential for assessing the Global Influenza Vaccine Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).
Market Share Analysis:
The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Influenza Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Influenza Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Influenza Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Influenza Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Influenza Vaccine Market?
6. What is the market share of the leading vendors in the Global Influenza Vaccine Market?
7. What modes and strategic moves are considered suitable for entering the Global Influenza Vaccine Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Influenza Vaccine Market, by Vaccine Type, 2022 vs 2030
- 4.3. Influenza Vaccine Market, by Age Group, 2022 vs 2030
- 4.4. Influenza Vaccine Market, by Administration Route, 2022 vs 2030
- 4.5. Influenza Vaccine Market, by Distribution Channel, 2022 vs 2030
- 4.6. Influenza Vaccine Market, by Region, 2022 vs 2030
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing Prevalence of Respiratory Disorders
- 5.1.1.2. Immunization as a Major Public Health Measures for the Prevention of Influenza Virus Infection
- 5.1.1.3. Clinical Trials and Vaccine Developments in Pipeline for Seasonal Influenzas
- 5.1.1.4. Government Initiatives Supporting Respiratory Health
- 5.1.2. Restraints
- 5.1.2.1. Lack of Inadequate Delivery Infrastructure & Limited Awareness
- 5.1.3. Opportunities
- 5.1.3.1. Increasing R&D Expenditure by Leading Market Players
- 5.1.3.2. Increasing Vaccine Availability through Distribution and Development Collaborations
- 5.1.3.3. Several Vaccine Candidates under Development against Animal Influenza A Virus
- 5.1.4. Challenges
- 5.1.4.1. Customers Trust and Confidence in Respiratory Disease Vaccination
- 5.1.4.2. Vaccine Research and Development are getting Challenged by the Constant Variations in Strains
- 5.1.1. Drivers
- 5.2. Market Trends
- 5.3. Cumulative Impact of COVID-19
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework
- 5.9. Client Customization
- 5.9.1. COVID: Eye on Proactive Vaccine Development
- 5.9.2. Shift to Retail Pharmacies for Immunizations
6. Influenza Vaccine Market, by Vaccine Type
- 6.1. Introduction
- 6.2. Inactivated
- 6.3. Live Attenuated
- 6.4. Recombinant
7. Influenza Vaccine Market, by Age Group
- 7.1. Introduction
- 7.2. Adolescent Vaccination
- 7.3. Adult Vaccination
- 7.4. Infant Vaccination
8. Influenza Vaccine Market, by Administration Route
- 8.1. Introduction
- 8.2. Intramuscular
- 8.3. Intranasal
- 8.4. Oral
9. Influenza Vaccine Market, by Distribution Channel
- 9.1. Introduction
- 9.2. Government Medical Office
- 9.3. Hospital & Clinic
- 9.4. Retail Pharmacy
- 9.5. Urgent Care Unit
10. Americas Influenza Vaccine Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
11. Asia-Pacific Influenza Vaccine Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
12. Europe, Middle East & Africa Influenza Vaccine Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
14. List of Company Mentioned
15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
